Get the Stockscreener App
3.05
1.33%
0.04
After Hours:
3.09
0.04
+1.31%
Cvrx Inc stock is traded at $3.05, with a volume of 855.67K.
It is up +1.33% in the last 24 hours and down -44.44% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$3.01
Open:
$2.99
24h Volume:
855.67K
Relative Volume:
1.16
Market Cap:
$81.26M
Revenue:
$59.07M
Net Income/Loss:
$-52.66M
P/E Ratio:
-1.5174
EPS:
-2.01
Net Cash Flow:
$-40.16M
1W Performance:
+3.39%
1M Performance:
-44.44%
6M Performance:
-64.08%
1Y Performance:
-60.39%
1-Day Range:
$2.96
$3.11
1-Week Range:
$2.81
$3.175
52-Week Range:
$2.20
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
3.05 | 75.66M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRX stock edges higher as investors watch neuromodulation growth - AD HOC NEWS
CVRX stock benefits as Barostim heart failure therapy gains new Medicare Advantage coverage - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx Secures Devoted Health Coverage for Barostim Therapy - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - PR Newswire
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - qz.com
CVRx has an activist investor urging it to get acquired - massdevice.com
CVRx Responds to Letter from Pointillist Family Office - marketscreener.com
CVRx responds to shareholder letter on company valuation - Investing.com
CVRx earns new Medicare Advantage coverage policy for Barostim - massdevice.com
CVRx Inc. Faces Securities Law Investigation Over Revenue Guidance Cut and DOJ Demand - kalkine.ca
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Nigeria
Jorey Chernett, Owner of More Than 5.5% of Ou - Moomoo
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - globenewswire.com
Jorey Chernett Urges Board to Launch Sale Process - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Law firm investigates CVRx for possible securit... - Pluang
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com South Africa
CVRX Q2 2026 Earnings: Modest EPS Beat Offset by 10.71% Share SlidePositive Surprise Momentum - Vinanet
Cantor cuts CVRx stock price target on sales execution challenges - Investing.com
Cantor Fitzgerald Issues Pessimistic Forecast for CVRx (NASDAQ:CVRX) Stock Price - MarketBeat
Johnson & Johnson Invests $20.69 Billion in CVRx, Inc. $CVRX - MarketBeat
CVRX Q2 2026 Earnings: Narrower-Than-Expected Loss Fuels 4.76% Stock GainDividend Increase Stocks - Vinanet
CVRx, Inc. (CVRX) investor Jorey Chernett discloses 5.5% beneficial stake - Stock Titan
Cvrx COO Brent Binkowski sells $3,338 in company stock By Investing.com - Investing.com South Africa
CVRX Q2 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 7.7%Guidance vs Actual - vinanet.vn
Cvrx COO Brent Binkowski sells $3,338 in company stock - Investing.com
Cvrx COO Brent Binkowski buys $76,432 in company stock By Investing.com - Investing.com Australia
CVRx (NASDAQ:CVRX) COO Brent Binkowski Buys 26,223 Shares of Stock - MarketBeat
Cvrx COO Brent Binkowski buys $76,432 in company stock - Investing.com
CVRx (CVRX) COO Brent Binkowski purchases 26,223 shares in open-market buy - Stock Titan
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares - Moomoo
CVRx (CVRX) Q2 2026 Earnings Call Transcript - AOL.com
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages - GlobeNewswire
CVRx (CVRX) COO executes 1,309-share sell-to-cover under Rule 10b5-1 plan - Stock Titan
Block & Leviton investigates CVRx for possible securities law violations after revenue guidance cut. - Pluang
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches - MarketBeat
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CVRx chief revenue officer exits amid slowing sales and execution concerns - The Business Journals
CVRx replaces chief revenue officer amid sales transition - The Globe and Mail
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Binkowski Brent | CHIEF OPERATING OFFICER |
Aug 12 '26 |
Sale |
2.55 |
1,309 |
3,338 |
30,291 |
| Adamson Philip B. | Chief Medical Officer |
Mar 02 '26 |
Sale |
7.90 |
1,262 |
9,973 |
61,578 |
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):